Last reviewed · How we verify
NCT07308587
Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture
trial testing Chest tube insertion in Intercostal Nerve Injury in 100 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Sunnybrook Health Sciences Centre |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 January 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Chest tube insertion
Conditions studied
- Intercostal Nerve Injury — all drugs for Intercostal Nerve Injury →
Sponsor
Sunnybrook Health Sciences Centre — full company profile →
Who can join
18 and older, any sex, with Intercostal Nerve Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Traumatic rib fractures are common injuries following blunt chest trauma, often requiring chest tube insertion to manage complications such as pneumothorax or haemothorax. However, chest tube placement can lead to intercostal nerve injury, resulting in intercostal neuralgia-a debilitating condition characterized by chronic, neuropathic pain along the intercostal nerves. Despite its clinical significance, the incidence, risk factors, and long-term outcomes of intercostal neuralgia in this patient population remain poorly understood. Chronic pain following thoracic trauma, including intercostal neuralgia, has been shown to significantly impair quality of life and functional outcomes, leading to prolonged disability and increased healthcare utilization. Current literature highlights the need for better understanding and management of this condition, particularly in patients undergoing invasive procedures such as chest tube insertion. This study aims to prospectively evaluate the development of intercostal neuralgia in patients with chest tube insertion following traumatic rib fractures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07308587
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Sunnybrook Health Sciences Centre trials
Trials by the same sponsor.
- NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
- NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
- NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
- NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
- NCT07275892 — Pilot Feasibility Trial of a Peer Support Program for Trauma Survivors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07308587 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
- Last refreshed: 29 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07308587.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing